On Thursday evening, Payday 3 was launched. The game reached around 220,000 concurrent players durin...
I torsdags kväll lanserades Payday 3. Spelet nådde omkring 220 000 samtidiga spelare under lansering...
Redeye somewhat lowers its forecasts and Base Case for Hexatronic, following the softer sales outloo...
Movinn announced on September 21st, that the company launches a third Swedish market in the city of ...
Today, BioInvent announced the initiation of the phase IIa monotherapy part of the study of BI-1808,...
Yesterday, Carasent announced that, following a review of the company’s capital structure, its board...
Crunchfish has announced a 60% guaranteed SEK 85 million rights issue.
As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expec...
Initiates strategic review to evaluate funding and ownership No timeline; FY'23 guidance unchanged W...
Travere, with its conditionally approved FILSPARI, is the only Tarpeyo alternative for US patients.
Redeye endorses the first results from Enzymatica’s ongoing independent clinical study at the Univer...
Redeye shares its takeaways from the Digitalize and Automate 2023 event – focusing on Effie AI and A...
Redeye comments on Optomed’s directed share issue, raising EUR4.
Redeye is positive to the news that Waystream continues to receive orders from City networks.
Syncro Group (alt. ”Koncernen”) har tidigare presenterat sin Q2-rapport vilken kom in något svagare ...
Duell released a profit warning ahead of the FY 2023 earnings which will be published 9th of October...
Yesterday, Vertiseit announced the divestment of its transportation business.
Redeye comments on the additional data presented from the phase IIa study with ACD440 in neuropathic...
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...
Recently (Monday Sep 18), those who had purchased more expensive special editions of Payday 3 were g...
